[-] Show simple item record

dc.contributor.authorDudley, Timothyeng
dc.contributor.authorParker, Sandieng
dc.date.issued2004eng
dc.description.abstractIn general, about 50% to 70% of patients respond to nedocromil (SOR: A, multiple RCTs and meta-analyses). Unfortunately, which patients respond is not predictable from clinical parameters. Nedocromil is worth trying in mild persistent asthma, particularly for children where the parents are worried about the growth issues associated with inhaled steroids. Side effects (sore throat, nausea, and headache) are mild and infrequent. Maximal efficacy is usually seen after 6 to 8 weeks.eng
dc.identifier.urihttp://hdl.handle.net/10355/3190eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2004 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 53, no. 11 (November 2004): 927-928.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectbiologic outcomeeng
dc.subjectclinical outcomeeng
dc.subjectexacerbation rateseng
dc.subjectsteroidseng
dc.subject.lcshSteroid drugseng
dc.subject.lcshAsthmaeng
dc.titleIs nedocromil effective in preventing asthmatic attacks in patients with asthma?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record